Niacin can raise good cholesterol in older heart patients, but even though it does that well, it doesn’t help shrink artery plaque any more than statins alone.
Scientific Claim
In older adults with established atherosclerosis and controlled LDL, extended-release niacin at 1500 mg daily increases HDL cholesterol by approximately 17% (from 1.4 to 1.6 mmol/L) over 18 months compared to placebo, but this increase does not translate to greater carotid plaque regression.
Original Statement
“After 18 months, high density lipoprotein cholesterol was higher with statins plus niacin compared with statins alone (1.6±0.4 vs 1.4±0.4 mmol/L p<0.001)... There was no difference in the rate of regression between groups (p=0.49).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The RCT design with precise lipid measurements and MRI outcomes supports definitive causal language for both the HDL increase and the lack of plaque benefit.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether niacin-induced HDL elevation consistently fails to reduce plaque regression across populations with controlled LDL.
Whether niacin-induced HDL elevation consistently fails to reduce plaque regression across populations with controlled LDL.
What This Would Prove
Whether niacin-induced HDL elevation consistently fails to reduce plaque regression across populations with controlled LDL.
Ideal Study Design
A meta-analysis of all RCTs measuring both HDL change and carotid/coronary plaque volume via MRI or IVUS in adults ≥65 on statins, comparing niacin (≥1500 mg/day) to placebo, with subgroup analysis by baseline HDL.
Limitation: Cannot determine if niacin benefits subgroups with very low baseline HDL.
Randomized Controlled TrialLevel 1bIn EvidenceCausal link between niacin-induced HDL rise and plaque regression in this population.
Causal link between niacin-induced HDL rise and plaque regression in this population.
What This Would Prove
Causal link between niacin-induced HDL rise and plaque regression in this population.
Ideal Study Design
A double-blind RCT of 300+ adults ≥65 with atherosclerosis and LDL <2.6 mmol/L, randomized to niacin 1500 mg/day, placebo, or a non-HDL-raising agent (e.g., ezetimibe), with primary outcome as plaque regression and secondary as HDL change.
Limitation: Does not test whether HDL elevation itself is causally protective.
Prospective Cohort StudyLevel 2bAssociation between magnitude of HDL increase and plaque regression in real-world niacin users.
Association between magnitude of HDL increase and plaque regression in real-world niacin users.
What This Would Prove
Association between magnitude of HDL increase and plaque regression in real-world niacin users.
Ideal Study Design
A prospective cohort of 1000+ adults ≥65 on statins who initiate niacin, tracked for 2 years with serial HDL and carotid MRI, analyzing whether the degree of HDL increase predicts plaque regression after adjusting for LDL and statin dose.
Limitation: Cannot prove causation due to confounding by adherence and lifestyle.
Evidence from Studies
Supporting (1)
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study
The study found that taking niacin raised 'good' cholesterol in older adults, just like the claim says, but it didn’t make the fatty plaques in their neck arteries shrink any more than taking a placebo did.